Important steps forward in the anti-ageing therapy against metastases

Congratulations to Prof. Alimonti and his Molecular Oncology team at Institute of Oncology Research in Bellinzona, Switzerland, who discovered a genetic factor that determines whether ageing prostate cancer cells either die or become more aggressive. They have now found the genetic switch that determines the fate of senescent cells: the gene TIMP1. If this gene is inactive or absent in patients, f...
More

Congratulations to Prof. Alimonti and his Molecular Oncology team on receiving the Prostate Cancer Foundation Challenge Award

Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this prestigious award for their work on targeting the host microbiota to reverse therapeutic resistance in lethal prostate cancers. Microbiota are microorganisms living in symbiosis with the host reported ...
More

New International PhD Program in Cancer Biology and Oncology 2020-2021

PhD at Institute of Oncology Research (IOR) means full immersion in a dynamic, challenging and intellectual community of students coming from different countries. The IOR provides high-level scientific education both for undergraduate students, experimental diploma thesis as well as graduate students. The PhD program, which includes seminars, lectures, classes and an annual retreat, is carried out...
More

EPFL, SUPSI and IOR receive a Swiss National Science Foundation (SNFS) grant within the NRP 78 “Covid-19” programme to develop a microfluidics device to detect SARS-CoV-2 virus

The project “Development of a microfluidic platform for real-time detection of SARS-CoV-2 virus based on multifunctional silica membrane biosensors” (MicroCoVSens) aims to realize a portable device for real-time detection of SARS-CoV-2 virus from saliva samples through minimal reagents consumption, without preparation requirements, at hand of non-specialist personnel. The group headed by Prof. Ber...
More

IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19

The so-called "androgen-deprivation" treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated to USI) based on health data obtained from the Veneto region in Italy has observed a lower risk of developing the coronavirus disease for men subject to this type of therapy. The study, performed in co...
More

Tiziano Bernasocchi awarded “PhD in Life Sciences” from the University of Lausanne

Tiziano Bernasocchi, molecular biologist in the Prostate Cancer Genome group of Prof. Jean-Philippe Theurillat, successfully defended his Ph.D. on April 21st, 2020, from the University of Lausanne. He presented the work entitled: Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer.  The research work elucidates an enigmatic finding of comprehensive prostate canc...
More